CLSN: DSMB Recommends Continuing to Dose Patients in OVATION 2 Study…
By David Bautz, PhD
NASDAQ:CLSN
READ THE FULL CLSN RESEARCH REPORT
Celsion’s Return On Capital Employed Insights
According to Benzinga Pro data, during Q4, Celsion (NASDAQ:CLSN) posted sales of $125.00 thousand. Earnings were up 21.98%, but Celsion still reported an overall loss of $4.22 million.
Earnings Scheduled For March 31, 2022
Companies Reporting Before The Bell
• Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter.
Celsion Receives $1.4M From Sale Of Its New Jersey State Net Operating Losses
Non-dilutive funding further strengthens balance sheet and
extends current operating runway through 2024
Additional $3.5 million of unused state NOLs expected to be sold in future years
LAWRENCEVILLE, N.J., Feb.
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation To Continue Dosing Patients In Phase II Portion Of OVATION 2 Study With GEN-1 In Advanced Ovarian Cancer
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
OVATION 2 Study is
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers
Epizyme (NASDAQ:EPZM) shares increased by 7.3% to $1.32 during Tuesday's after-market session. Epizyme's trading volume hit 240.6K shares by close, accounting for 10.7% of its average volume over the last 100 days. The company's market cap stands at $140.0 million.
Celsion Corp Highlights In-Process Vaccine Candidate
Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation DNA-based vaccines, announces it has engaged BIOQUAL, Inc., a preclinical testing
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers
Mustang Bio (NASDAQ:MBIO) shares rose 6.9% to $1.39 during Friday's after-market session. The company's market cap stands at $129.8 million.
